[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"craving\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:craving":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,83,108,134,158,190,222,245,281],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100490484","state-dependent-interoception-value-based-decision-making-and-introspection-100490484",false,"NCT05666726","State-dependent Interoception, Value-based Decision-making, and Introspection","State-Dependent Interoception, Value-Based Decision Making, and Introspection","* INCLUSION CRITERIA:\n\nSubject selections will be equitable among those individuals who meet the inclusion criteria. Every effort will be made to balance sex and race. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* All sexes; Age 18 to 55.\n* Able to read and write in English to guarantee understanding of all written and spoken instructions, which are in English.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nFor all experiments:\n\n* Unable to comply with study procedures or follow-up visits\n* Has any serious or unstable medical condition or history that in a clinician s assessment implies a cardiovascular, neurological, or physical risk from the study procedures performed to induce negative valence states. This may include chronic systemic disorders that could worsen due to stress (e.g. uncontrolled hypertension, coronary artery disease for example a history of myocardial infarction or stable or unstable angina, or diabetes)\n* Has any current psychiatric diagnosis (based on SCID or the MINI Mini International Neuropsychiatric Interview) or no diagnosis but scores \\>=29 on Beck Depression Inventory II or \\>=26 on Beck Anxiety Inventory\n* Meets criteria for diagnosis of any substance-related or addictive disorder, or endorses any kind of problematic gambling behavior or problematic media-based addictive behavior (such as videogames, social-networking, online shopping, etc.)\n* Regular use of psychoactive medications or psychoactive substances\n* Regular use of corticosteroids\n* Is pregnant\n\nFor stress and pain induction:\n\n* Has a major medical condition or medical history that in a clinician s assessment could affect temperature sensitivity, pain thresholds, or ability to comply with study procedures. This may include cardiovascular, autonomic, neurological, psychiatric, or chronic systemic disorders (including but not limited to stroke, blindness, deafness, history of brain damage, neurodegenerative, neurotoxic or demyelinating disorder, or diabetes)\n* Has a medical condition that in a clinician s assessment might affect somatosensation (e.g., Raynaud s disease, peripheral neuropathy, or circulatory disorder)\n\nFor pain induction:\n\n* Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)\n* Has a dermatological condition such as scars or burns, or has had a tattoo in the testing region within the previous 4 weeks that might influence cutaneous sensibility\n* Regular and recent use of prescription or over-the-counter medication that has a significant effect on pain or heat perception. These include medications such as centralacting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbiturates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an as needed basis is acceptable as long as the last dose taken was within 5 half-lives of testing.\n\nFor craving induction:\n\n* Has a condition that in a clinician s assessment could preclude the ability to hold 4-6 hours of fasting or that is associated with a risk of hypoglycemia (such as diabetes, kidney disease, insulinoma, adrenal or pituitary tumors or disorders, or anorexia nervosa)\n* Is currently engaged in any kind of diet medically- or self-prescribed or endorses a very strong desire to start a diet that involves eliminating or decreasing carbohydrate consumption\n* Has a history of food allergies such as tree-nut or peanut allergy.\n\nFor fMRI experiments:\n\n* Individuals with conditions that could pose a risk relating to the safety of the fMRI procedure but do not meet specific exclusion criteria for all experiments or for specific inductions will be excluded from the MRI portion of the protocol but may participate in the non-MRI sessions. Such conditions include:\n* Those with ferromagnetic metal in the cranial cavity or eye (e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body)\n* Those with an abnormality on a structural MRI\n* Those with an implanted cardiac pacemaker or auto-defibrillator\n* Those with an insulin pump\n* Those with an irremovable body piercing\n* Pregnancy (based on urine test completed within 24 hours prior to scan)\n* Left-handed (only for fMRI experiments involving thermal pain stimulation)",true,"ALL","18 Years","55 Years",{"count":21,"type":22},900,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background:\n\nNegative emotional states can affect a person s behavior as they make decisions. For example, hunger may make people more impatient; they may then make riskier choices. Other negative emotional states that can change behavior include stress, pain, and sadness. By learning more about how emotions affect thinking and behavior in healthy people, researchers hope to better understand how to identify and treat people with mental disorders.\n\nObjective:\n\nTo learn how negative emotions affect the brain and decision-making behavior.\n\nEligibility:\n\nHealthy people aged 18 to 55 years.\n\nDesign:\n\nParticipants will have 3 clinic visits in 3 weeks.\n\nParticipants will fill out questionnaires. They will be asked about their personal history, their personality, and state of mind.\n\nFor 2 visits, participants will be assigned to different groups. Each group will experience 1 type of emotional stressor:\n\nSome participants will watch a video.\n\nSome will have to do arithmetic problems.\n\nSome will have heat applied to an arm or leg.\n\nSome will experience cold by immersing their hand in ice water.\n\nFor a snack craving test, some will be tempted by food after a 4-hour fast.\n\nDuring these tests, participants will have sensors attached to their bodies. They will be videotaped. Saliva samples will be collected.\n\nAfter the stressors, participants will do tasks on a computer. They will need to make choices.\n\nSome participants will perform these decision-making tasks while lying in a brain scanner for functional magnetic resonance imaging. The brain scan involves lying on a table that slides into a cylinder that takes images of the brain.\n\n...",[28,29,30,31,32],"Stress","Pain","Emotions","Craving","Frustration",[34,35,36,28,29,37],"Decision-Making","Interoception","Metacognition","Negative Emotion","RECRUITING","2026-06-27",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":42},"2023-07-25",{"date":46,"type":22},"2029-12-31",{"name":48,"class":49},"National Institute of Mental Health (NIMH)","NIH",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":50},"100604386","phase-2-cannabidiol-as-an-adjunct-treatment-for-alcohol-withdrawal-and-craving-100604386","NCT07148843","Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving","Inclusion Criteria\n\n* Meets DSM-5 criteria Moderate or Severe Alcohol Use Disorder\n* Age 21-65\n* Report at least one prior episode of alcohol withdrawal symptoms at least one day in duration that caused significant impairment in functioning (i.e., unable to attend work or engage in typical activities) AND\u002FOR required medications to manage symptoms.\n* Drinking at least 8 drinks a day over the two weeks prior to screening.\n* Negative human chorionic gonadotropin (hCG) on qualitative urine pregnancy screen\n* Shipley vocabulary score \\> 18, corresponding to 5th grade reading level.\n* Demonstrated understanding of informed consent and ability to consent to participation in the study.\n\nExclusion Criteria\n\n* Current or past alcohol-related medical complications including but not limited to cirrhosis of the liver, esophageal varices, pancreatitis, severe gastritis, hemoptysis, hematochezia, or melena.\n* Use of gabapentin, benzodiazepines, or other sedative-hypnotic medications within the week prior to admission\n* Regular use (e.g., more than twice a week) of cannabis or CBD products.\n* Regular use of benzodiazepines (e.g., twice a week or more) within the last three months\n* Meet DSM-5 criteria for moderate-to-severe substance use disorder (SUD), including Cannabis Use Disorder (except for alcohol and tobacco)\n* Urine drug screen indicating the presence of substances other than cannabis at screening.\n* Unstable and\u002For compromising medical or psychiatric conditions that would interfere with participant safety as determined by study physician.\n* Current pregnancy\n* BMI \\\u003C17\n* History of anorexia nervosa or bulimia in the past 2 years\n* History of seizures or seizure disorder outside of alcohol-withdrawal related seizures\n* Systolic blood pressure (SBP) \\> 180, Diastolic Blood Pressure (DBP) \\> 120 or pulse \\> 120 during screening or upon admission\n* Any of the following laboratory values during screening or upon admission:\n\n  * AST \\> 165 U\u002FL (normal range 19-55)\n  * ALT \\> 216 U\u002FL (normal range 19-72)\n  * Alkaline phosphatase \\> 378 U\u002FL (normal range 38-126)\n  * Total bilirubin \\>2.5 mg\u002Fdl (normal values=0.3-1.0 mg\u002FdL)\n  * Non-fasting glucose \\> 250 mg\u002Fml (normal range 65-179)\n  * Hematocrit \\\u003C 38 % (normal range 41-53)\n  * Hemoglobin \\\u003C 12 g\u002Fdl (normal range 13.5-17.5) or any other laboratory value significantly outside the normal range\n* Use of a prescription medication (except for birth control prescriptions) within 14 days of study entry, which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. This includes any medication in which CYP2C9, CYP2C19, CYP1A2, CYP2B10, or CYP3A4 enzymes are major metabolizers.\n* ECG with corrected QT interval (QTC) \\>\u002F= 500 ms and\u002For presence of clinically significant abnormality\n* Participation in other clinical trials within the past 60 days\n* Court-mandated participation in alcohol treatment or pending incarceration","21 Years","65 Years",{"count":60,"type":22},105,[62,63],"PHASE2","PHASE3","Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.",[66,67,31],"Alcohol Use Disorder (AUD)","Withdrawal From Addictive Substance; Detoxification",[69,70,71],"alcohol abstinence","alcohol withdrawal treatment","detoxification","NOT_YET_RECRUITING","2026-04-30",{"date":75,"type":42},"2026-05-01",{"date":77,"type":22},"2026-08-01",{"date":79,"type":22},"2030-10-31",{"name":81,"class":82},"Johns Hopkins University","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100627708","phase-2-endotoxin-exposure-to-examine-the-role-of-inflammation-in-alcohol-use-100627708","NCT07452146","Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use","Understanding the Role of Inflammation in Alcohol Use Disorder: An Inflammatory Challenge Using Lipopolysaccharide","Inclusion Criteria (AUD Group):\n\n1. Be between the ages of 21 and 65\n2. Meet current (i.e., past month) DSM-5 diagnostic criteria for moderate to severe AUD\n3. Be non-treatment seeking for AUD\n4. Report drinking at least 28 drinks per week if male (21 drinks per week if female) in the 28 days prior to consent.\n5. Must agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile:\n\n   * Oral contraceptives\n   * Contraceptive sponge\n   * Patch\n   * Double barrier\n   * Intrauterine contraceptive device\n   * Etonogestrel implant\n   * Medroxyprogesterone acetate contraceptive injection\n   * Complete abstinence from sexual intercourse\n   * Hormonal vaginal contraceptive ring\n\nInclusion Criteria (Control Group):\n\n(1) The control group will be age-, sex-, smoking status-, and BMI-matched healthy individuals who drink at or below moderate drinking levels (≤1 drink\u002Fday for females, ≤2 drinks\u002Fday for males) and have no lifetime history of AUD.\n\nExclusion Criteria (All Groups):\n\n1. Have a current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than alcohol and nicotine\n2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder\n3. Have current moderate to severe depression as indicated by a score of ≥ 21 on the Beck Depression Inventory - II (BDI-II)\n4. Have current suicidal ideation or lifetime history of suicide attempt as reported on the Columbia-Suicide Severity Rating Scale (C-SSRS)\n5. Have a positive urine screen for drugs other than cannabis;\n6. Have clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-R)\n7. Have an intense fear of needles or have had any adverse reactions to needle puncture\n8. Be pregnant, nursing, or planning to become pregnant while taking part in the study\n9. Have a body mass index (BMI) greater than 30\n10. Have a medical condition that may interfere with safe study participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes, autoimmune or inflammatory disease)\n11. Have clinically significant abnormal EKG\n12. Have \\> Grade 2 laboratory abnormalities, based on FDA Guidance Document \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\"\n13. Have any other circumstances that, in the opinion of the investigators, compromises participant safety\n14. To participate in the inflammatory challenge, participants must not show any of the following upon arrival to the inflammatory challenge study visit:\n\n    1. BrAC \\> 0.000 g\u002Fdl\n    2. clinical withdrawal (CIWA-R) score ≥ 10\n    3. blood pressure ≤ 90\u002F60 or ≥ 160\u002F120\n    4. resting pulse ≤ 50 beats\u002Fminute or \\> 100 beats\u002Fminute\n    5. temperature ≥ 99.5°F\n    6. recent (past 2 weeks) acute illness or vaccination\n    7. score of 10+ on Physical Sickness Symptoms Assessment",{"count":91,"type":22},64,[62],"The study design consists of a randomized, double-blind, placebo-controlled study of low dose endotoxin. Individuals with current AUD (n=32) and matched controls without AUD (n=32) will be randomly assigned to receive a single intravenous (I.V.) infusion of either low dose endotoxin (0.8 ng\u002Fkg of body weight) or placebo (same volume of 0.9% saline solution) to determine the acute and protracted role of inflammation in alcohol use.",[95,96,31],"Alcohol Use Disorder","Inflammatory Response",[98],"Endotoxin","2026-04-28",{"date":101,"type":42},"2026-05-04",{"date":103,"type":22},"2026-06",{"date":105,"type":22},"2028-07",{"name":107,"class":82},"University of California, Los Angeles",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":50},"100602062","phase-2-probenecid-administration-for-alcohol-craving-and-consumption-100602062","NCT07118618","Probenecid Administration for Alcohol Craving and Consumption","Probenecid, Pannexin 1 Channels for Alcohol Use Disorder","PROB2","Inclusion Criteria:\n\n* • Male or female, ≥18 years.\n\n  * women \\>7 drinks\u002Fweek; men \\>14 drinks\u002Fweek.\n  * meet moderate to severe AUD score for DSM-5 criteria.\n  * Breath Alcohol Content (BrAC)=0.00 at each visit.\n  * in good health as confirmed by medical history, physical examination and lab tests.\n  * willing to adhere to the study procedures.\n  * understand informed consent and questionnaires in English at an 8th grade level.\n\nExclusion Criteria:\n\n* • Women who are breastfeeding or positive urine test for pregnancy.\n\n  * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \\>150% of the upper normal limit, ALT\u002FAST \\>300% the UNL, creatinine clearance ≤60 dl\u002Fmin\n  * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses\n  * medications that reduce alcohol consumption (naltrexone, disulfiram).\n  * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration).\n  * history of suicide attempts in the last three years.\n  * current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.\n  * current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.\n  * current use of medications that may interact with probenecid.\n  * history of hypersensitivity to sulfa drugs.",{"count":117,"type":22},120,[62],"This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g \u002Fday) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.",[66,121,31],"Alcohol Consumption",[123,124,31,125],"AUD","Probenecid","Alcohol","2026-03-14",{"date":128,"type":42},"2026-03-17",{"date":126,"type":42},{"date":131,"type":22},"2030-12-31",{"name":133,"class":82},"Brown University",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":50},"100560879","early-phase-1-advancing-vr-based-attentional-bias-as-a-biomarker-for-tobacco-use-disorder-100560879","NCT06582888","Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder","VR","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Persons, aged 22+\n4. Ability to take oral medication and be willing to adhere to the dosing regimen\n5. For participants able to become pregnant: use of highly effective contraception during study enrollment\n6. Current daily tobacco use (use on 7 days per week, on average, ≥5 cigarettes per day, in the previous 3 months)\n7. Tobacco use history ≥3 years\n8. Endorsement of past week nicotine craving\n\nExclusion Criteria:\n\n1. Contraindications\u002Fconditions with special precautions for varenicline treatment (i.e., history of serious hypersensitivity or skin reactions to varenicline, history of severe renal impairment, seizures, severe cardiovascular disease, chronic or severe nausea, Stevens-Johnson syndrome, erythema multiforme, pregnancy or nursing)\n2. Medical or psychiatric history affecting brain development (i.e., history and\u002For treatment of neurologic disorders, severe head trauma with loss of consciousness \\>2 minutes, or current severe Diagnostic and Statistical Manual 5th edition (DSM-5) psychiatric disorders other than tobacco use disorders)\n3. Current suicidal ideation or history of suicide attempt or self-mutilatory acts in the past 12 months\n4. Other recreational drug use in the past 30 days (besides alcohol and cannabis) verified by oral and urine fluid toxicology\n5. Visual\u002Fvestibular problems that may make task completion difficult (i.e., motion sickness, difficulty balancing, blindness)\n6. Treatment seeking for tobacco use disorder\u002Fintent to quit within 30 days","22 Years",{"count":143,"type":22},200,[145],"EARLY_PHASE1","The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (n per group=100; total N=200). Following eight days of titration, participants will be assessed again on the VR Nicotine Cue Exposure paradigm. They will then be followed via mobile assessments for eight days on target dose of varenicline, and 30-days post assessment by phone, to assess short-term nicotine use behaviors.",[148,31],"Nicotine Addiction","2026-03-12",{"date":151,"type":42},"2026-03-16",{"date":153,"type":42},"2024-11-19",{"date":155,"type":22},"2028-08-15",{"name":157,"class":82},"University of California, San Diego",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":50},"100624474","tdcs-for-social-media-addiction-100624474","NCT07410104","tDCS for Social Media Addiction","Impact of Non-Invasive Neuromodulation on Social Media Addiction","tDCS4SMA","Inclusion Criteria:\n\n* Age ≥18 years.\n* Availability to participate in all study phases\u002Fsessions.\n* IAT score ≥31 (moderate to severe level).\n\nExclusion Criteria:\n\n* Diagnosis of depressive, anxiety, or bipolar disorders with recent symptoms; schizophrenia; psychotic disorders; or autism spectrum disorder.\n* Recent psychotropic medication use or dose change within the last 3 months.\n* Current need for inpatient care or ongoing psychotherapy.\n* History of dizziness or seizures\u002Fconvulsions.\n* Contraindications to tDCS, including pregnancy, metallic implants, tumors, prior brain surgery, or significant anatomical brain alterations.",{"count":167,"type":22},60,[25],"The goal of this clinical trial is to learn whether transcranial direct current stimulation (tDCS), a non-invasive brain stimulation, can reduce \"craving\" and problematic levels of social media\u002Finternet use in university students.\n\nThe main questions it aims to answer are:\n\n* Does active tDCS reduce craving to use social media during the intervention period compared with sham stimulation and no stimulation?\n* Does active tDCS reduce internet\u002Fsocial media addiction severity (measured with the Internet Addiction Test, IAT) compared with sham stimulation and no stimulation, and are any effects still present at follow-up? Researchers will compare three groups-active tDCS, sham tDCS (a simulation where stimulation is stopped after the first seconds), and a control group (no stimulation)-to see whether changes are due to tDCS rather than placebo effects or time.\n\nParticipants will:\n\n* Complete an initial screening and baseline questionnaires (a sociodemographic questionnaire and the IAT).\n* Be randomly assigned to one of three groups: active tDCS, sham tDCS, or control (no stimulation).\n* Complete the IAT again after the intervention and again about 5 weeks later (follow-up), along with questions about social media use habits.\n\nDuring intervention, participants in active tDCS and sham tDCS will:\n\n* Attend 10 sessions over 2 consecutive weeks (Monday-Friday), with each session lasting about 30 minutes; mobile phone use is not allowed during sessions.\n* Rate craving on a Visual Analogue Scale (VAS) at the start and end of each session.\n\nThis study will be conducted with university students in the Greater Lisbon area and will follow double-blind procedures for the active vs sham conditions (participants and researchers will not know the assigned condition until the end of the study).",[171,172,31,173],"Social Media Addiction","Craving to Use Social Media","Internet Addiction",[175,176,177,31,178,179,180],"Social media addiction","Internet addiction","Digital addiction","Transcranial direct current stimulation","tDCS","Non-invasive neuromodulation","2026-02-18",{"date":183,"type":42},"2026-02-20",{"date":185,"type":22},"2026-03",{"date":187,"type":22},"2026-09",{"name":189,"class":82},"Egas Moniz - Cooperativa de Ensino Superior, CRL",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":50},"100605023","examining-the-effectiveness-of-dynamic-visual-noise-dvn-for-reducing-alcohol-cravings-and-consumption-in-college-students-100605023","NCT07157124","Examining the Effectiveness of Dynamic Visual Noise (DVN) for Reducing Alcohol Cravings and Consumption in College Students","A Theory-Informed Examination of a Brief Visuospatial Intervention and Its Mechanisms for Reducing Alcohol Cravings and Consumption","Inclusion Criteria:\n\n1. Must report being between the age of 18 and 29\n2. Must report drinking alcohol at least once per week on average over the past month\n3. Must report having drank beer or alcoholic seltzers in the past month\n4. Must endorse experiencing craving at least once per week over the past month, on average\n5. Must report not currently receiving nor planning to seek any other treatment for their alcohol use within the next 30 days\n6. Must report owning a personal electronic device with access to the Internet\n7. Must report owning or having access to a computer with access to the Internet\n\nExclusion Criteria:\n\n1. Major visual impairment (i.e., legal blindness or color blindness)\n2. History of seizures and\u002For diagnosed seizure disorder\n3. Current medical diagnosis provided by a qualified professional (i.e., psychologist, psychiatrist, neurologist) that is characterized by cognitive impairment (i.e., neurocognitive disorder due to traumatic brain injury, traumatic brain injury, HIV infection, post-concussive syndrome, and intellectual disability)\n4. Concussion in the past month\n5. A current diagnosis of any substance use disorder besides alcohol use disorder, as determined by a qualified professional (i.e., psychologist, psychiatrist)","29 Years",{"count":199,"type":22},62,[25],"The goal of this clinical trial is to examine whether dynamic visual noise (DVN), a short video array of rapidly moving black and white squares, reduces cravings for and consumption of alcohol in college students who drink alcohol and experience cravings for alcohol at least once a week on average. A second goal of this clinical trial is to examine whether changes in attentional bias towards alcohol (that is, the tendency to pay greater mental and visual attention towards alcohol over other things in one's environment) is a mechanism by which DVN reduces alcohol cravings and consumption.\n\nResearchers will compare DVN to static visual noise (SVN), which is a still image of black and white squares that has been used as a control condition for DVN in prior literature.\n\nParticipants will:\n\n1. Visit the laboratory once to complete the baseline data collection\n2. Watch the DVN or SVN every day for seven days (including the day of the laboratory visit)\n3. Complete daily follow-ups for six days following the day of the laboratory visit\n4. Complete a final follow-up on the seventh day following the laboratory visit",[31,203],"Alcohol Drinking",[205,206,207,208,209,210,211,212,213],"alcohol craving","dynamic visual noise","alcohol consumption","attentional bias","craving","alcohol","DVN","static visual noise","SVN","2025-12-21",{"date":216,"type":42},"2025-12-29",{"date":218,"type":42},"2025-09-22",{"date":187,"type":22},{"name":221,"class":82},"University of Wyoming",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":229,"minAge":18,"maxAge":19,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":50},"100460598","neurofeedback-based-on-near-infrared-spectroscopy-as-a-therapy-for-food-addiction-in-obese-subjects-100460598","NCT05277714","Neurofeedback Based on Near-infrared Spectroscopy as a Therapy for Food Addiction in Obese Subjects.","CaDOb","Inclusion Criteria:\n\n* Eligible for obesity surgery according to the 2009 French High Authority on Health (HAS) criteria (BMI ≥40 or BMI ≥35 with comorbidities)\n* Right-handed\n* Presenting a food addiction determined by the YFAS 2.0 questionnaire ;\n* Affiliated to a social security system;\n* Having given free and informed consent in writing.\n\nExclusion Criteria:\n\n* Psychotic psychiatric disorders (schizophrenic disorders and bipolar disorders);\n* Psychotropic drugs, except antidepressants stabilized for at least 3 weeks and benzodiazepines\n* Addiction to alcohol or other psychoactive substances (except tobacco);\n* History of bariatric surgery;\n* Current treatment in the nutrition unit;\n* Insufficient command of French;\n* Pregnant or breast-feeding woman;\n* Persons of legal age under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.\n* Contraindications to fMRI\n* Inability to perform the fNIRS procedure due to blockage or attenuation of the light at the capillary level","FEMALE",{"count":231,"type":22},50,[25],"The hypothesis is that the increase in dlPFC brain activity via near-infrared spectroscopy-based Neurofeedback (fNIRS-based NF) training based on near-infrared spectroscopy would allow an improvement of the eating behavior, thus promoting a long-term weight loss in obese subjects.\n\nPatients will be trained during a month with 8 NF sessions and results based on clinical data and different questionnaires results will be compared between inclusion and 3 months later",[235,31],"Obesity","2025-08-04",{"date":238,"type":42},"2025-08-08",{"date":240,"type":42},"2022-05-25",{"date":242,"type":22},"2026-12",{"name":244,"class":82},"Rennes University Hospital",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":263,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":280},"100524217","neurobehavioral-profiles-of-adaptive-stress-responses-in-individuals-with-alcohol-use-disorder-100524217","NCT06105853","Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder","Towards Neurobehavioral Profiles and Models of Adaptive Stress Responses and Resilience in Individuals With Alcohol Use Disorder","A03","Inclusion criteria are:\n\n* age between 16 and 65 years\n* meeting at least 2 criteria of an alcohol use disorder according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5), yet without the need for a therapeutic intervention\n* fluency in German\n* able to understand the study procedures and give informed consent\n* willingness to use a study smartphone\n\nExclusion criteria are:\n\n* current use of drugs or medications that interact with the central nervous system or the glucocorticoid system\n* contraindications for magnetic resonance imaging\n* medical history of bipolar disorder, psychotic disorder, schizophrenia or schizophrenic spectrum disorder, or substance use disorder other than alcohol, nicotine, or cannabis\n* medical history of severe head injury or other severe central nervous system disorders or other severe somatic disorders (e.g. liver cirrhosis)\n* pregnancy",{"count":254,"type":22},100,[25],"The goal of this observational study is to investigate longitudinal stress response profiles and adaptive versus non-adaptive stress responses in alcohol use disorder. The main questions the projects aims to answer are:\n\nWhat are the neurobehavioral underpinnings of adaptive stress responses and resilience to repeated stress exposure with regards to:\n\n* alcohol craving?\n* alcohol use?\n* their modulation by prior stress exposure, social interactions, coping strategies and individual health behavior?\n\nParticipants will:\n\n* be exposed to an established experimental stress-induction protocol, the Trier Social Stress Test\n* be exposed to their favorite drink in a bar lab environment\n* be assessed using fMRI to determine their neural alcohol cue reactivity, response inhibition, and emotion processing\n* conduct an ambulatory phase to assess stressors, alcohol craving, substance use and details on social interactions, health behavior and coping strategies using ecological momentary assessment tools.",[95,258,259,31,260,261,262],"Stress Reaction","Social Stress","Relapse","Addiction, Alcohol","Risk Behavior",[264,265,209,266,267,268,269,270],"stress","resilience","sensitization","habituation","cortisol","ecological momentary assessment","alcohol use disorder","2025-04-28",{"date":273,"type":42},"2025-04-29",{"date":275,"type":42},"2023-12-01",{"date":277,"type":22},"2027-06-30",{"name":279,"class":82},"Central Institute of Mental Health, Mannheim",2,{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":297,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":50},"100535090","using-neurofeedback-to-understand-the-relationship-between-stress-and-alcohol-consumption-100535090","NCT06247306","Using Neurofeedback to Understand the Relationship Between Stress and Alcohol Consumption","Probing the Influence of Neural Stress Responses on Problematic Alcohol Use With Real-time fMRI Neurofeedback (C04)","NeuStress","Inclusion Criteria:\n\n* Age 18-65 years\n* Presence of 2 to a maximum of 5 criteria for alcohol use disorder according to DSM-5\n* no clinical necessity for detoxification treatment\n* participants may have a moderate cannabis use disorder and tobacco use disorder\n* Capacity for consent and ability to use self-assessment scales\n* Sufficient knowledge of German\n* Willingness to use a mobile phone with Android operating system\n\nExclusion Criteria:\n\n* Lifetime diagnosis of bipolar or psychotic disorder or a substance use disorder according to Diagnostical and Statistical Manual of Mental Disorders - 5 (DSM-5) that is not alcohol, cannabis, or tobacco use disorder\n* Current substance use other than cannabis and tobacco\n* Current diagnosis of one of the following conditions according to DSM-5: (hypo)manic episode, major depression, generalized anxiety disorder, post-traumatic stress disorder, borderline personality disorder, or obsessive-compulsive disorder\n* History of severe head trauma or other severe central neurological disorders (dementia, Parkinson\\'s disease, multiple sclerosis)\n* Pregnancy or lactation\n* Use of medications known to interact with the central nervous system within the last 10 days; testing at least four half-lives after the last dose\n* Exercising the prerogative of the \\"Right not to know\\" in the context of incidental findings during an examination or investigation",{"count":290,"type":22},102,[25],"In this research project, the aim is to discover the role specific brain networks play in the relationship between stress reactions and the desire for alcohol and alcohol consumption. To investigate this question, various brain imaging methods as well as cognitive tasks are combined. Various questionnaires are sampled and brain scans are conducted.\n\nIndividuals interested in participating in the study have to fulfill certain criteria...\n\n* no serious medical or mental health diagnosis\n* problematic alcohol drinking habits\n* interested in improving drinking habits\n\n  ...and undergo various non-invasive procedures\n* filling out several questionnaires concerning personality and habits\n* undergoing a mental performance task while being in a brain scanner (MRI)\n* attempting to regulate their own brain activity while lying in the MRI scanner\n* filling out an electronic diary for 6 weeks - concerning daily mood, stress, and alcohol habits\n\nParticipants will be randomly allocated to either one of 2 experimental groups. Both groups undergo the same tasks, receive the same instructions and only differ regarding some aspects of the brain self-regulation task .",[294,31,295,296],"Alcohol Abuse","Psychosocial Stressor","Neural Stress Response",[298,299,300,301,268,302],"functional Magnetic Resonance Imaging (fMRI)","psychosocial stress","real-time fMRI neurofeedback (rtfMRI neurofeedback)","problematic alcohol use","Ecological momentary assessment (EMA)","2025-01-22",{"date":305,"type":42},"2025-01-23",{"date":307,"type":42},"2024-03-01",{"date":309,"type":22},"2027-07-01",{"name":279,"class":82}]